- Home
- RNG vs DYN Comparison
RNG vs DYN Comparison
Compare RNG & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNG
- DYN
- Stock Information
- Founded
- RNG 1999
- DYN 1984
- Country
- RNG United States
- DYN United States
- Employees
- RNG N/A
- DYN N/A
- Industry
- RNG EDP Services
- DYN Medicinal Chemicals and Botanical Products
- Sector
- RNG Technology
- DYN Health Care
- Exchange
- RNG Nasdaq
- DYN Nasdaq
- Market Cap
- RNG 3.1B
- DYN 2.6B
- IPO Year
- RNG 2013
- DYN 2020
- Fundamental
- Price
- RNG $34.59
- DYN $14.32
- Analyst Decision
- RNG Buy
- DYN Strong Buy
- Analyst Count
- RNG 14
- DYN 10
- Target Price
- RNG $41.29
- DYN $50.70
- AVG Volume (30 Days)
- RNG 1.1M
- DYN 1.8M
- Earning Date
- RNG 02-18-2025
- DYN 03-04-2025
- Dividend Yield
- RNG N/A
- DYN N/A
- EPS Growth
- RNG N/A
- DYN N/A
- EPS
- RNG N/A
- DYN N/A
- Revenue
- RNG $2,357,154,000.00
- DYN N/A
- Revenue This Year
- RNG $9.97
- DYN N/A
- Revenue Next Year
- RNG $7.35
- DYN N/A
- P/E Ratio
- RNG N/A
- DYN N/A
- Revenue Growth
- RNG 9.33
- DYN N/A
- 52 Week Low
- RNG $26.98
- DYN $13.99
- 52 Week High
- RNG $42.19
- DYN $47.45
- Technical
- Relative Strength Index (RSI)
- RNG 45.89
- DYN 22.14
- Support Level
- RNG $33.10
- DYN $13.99
- Resistance Level
- RNG $34.38
- DYN $15.90
- Average True Range (ATR)
- RNG 1.08
- DYN 1.46
- MACD
- RNG 0.03
- DYN -0.58
- Stochastic Oscillator
- RNG 50.19
- DYN 4.62
About RNG RingCentral Inc.
RingCentral is a unified communications as a service, or UCaaS, provider. Its software helps users communicate and collaborate via voice, video, and messaging across all device types and all from one platform. RingCentral helps customers modernize and move from legacy on-premises systems to modern, cloud-based systems. Beyond its core RingCentral MVP solution, RingCentral also offers a cloud-based contact center solution, a stand-alone video meetings solution, and webinars.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a biotechnology company focused on providing therapeutics for patients with genetically driven diseases. The company overcomes the limitations of muscle tissue delivery and modern oligonucleotide therapeutics for muscle diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. The company's product candidates are DYNE-101 and DYNE-251, both are in the ongoing phase 1/2 clinical trial.